A Phase 3 interventional study of tolvaptan and Fluid Restriction in Hyponatremia, Dilutional Hyponatremia and Inappropriate ADH Syndrome, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Terminated at 56 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-30.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing tolvaptan in Hyponatremia — none open to participants now, none under way, none of them phase 3. Tolvaptan · Hyponatremia.
Among the 20 studies testing tolvaptan in Hyponatremia, this one is the 5th largest by enrollment, is the only one that started in 2010, is one of 9 in phase 3, and was the 6th registered.
164 studies on the registry are indexed under Hyponatremia; 16 are open to participants now.
Browse Hyponatremia studies →None of the 20 studies testing tolvaptan in Hyponatremia is open now. The open studies under Hyponatremia, anywhere →
Tolvaptan: first FDA approval 2009 (SAMSCA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 14 Hyponatremia studies recruiting now, 13 (93%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 10 · Phase 4 7
First in 2003; this study’s year is marked. 1 started in 2010.
This study's enrollment of 124 is above the median of 60 across 97 interventional studies indexed under Hyponatremia.
Median enrollment 55 across the 20 interventional studies. Of the 16 that completed or were terminated, 7 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 20 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
17 studies in Hyponatremia by Otsuka Holdings Co., Ltd.: none open now, none under way, none of them phase 3. Of 15 finished, 8 (53%) have results posted.
Among the 17 studies in Hyponatremia by Otsuka Holdings Co., Ltd., this one is the 4th largest by enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2010, is one of 8 in phase 3, and was the 5th registered.
Otsuka Holdings Co., Ltd.’s Hyponatremia studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing tolvaptan in Hyponatremia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 17 in Hyponatremia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if hospitalized patients with symptomatic hyponatremia treated with tolvaptan are in the hospital for less time than patients treated with fluid restriction. The study will also test if tolvaptan is better than fluid restriction in treating the symptoms of hyponatremia in hospitalized patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral tablet without fluid restriction. After the initial dose, daily dose may be titrated based on response.
Drug: tolvaptan
Placebo tablet with prescribed fluid restriction. After the initial dose, level of fluid restriction may titrated based response.
Other: Fluid Restriction
15 mg titrated to 30 mg then 60 mg once daily as oral tablet for up to 7 days based on response.
Also known as: SAMSCA, OPC-41061, OPC-156
Placebo tablet once daily with prescribed daily fluid intake of 1500 mL, then intensifying to 2 lower volumes of fluid intake for up to 7 days based on response. Since all particpants were blinded to treatment, titration to stricter fluid restriction followed the same algorithm as tolvaptan, increasing both the level of fluid restriction and increasing the placebo "dose"
Length of Hospital Stay (LoS)
LoS was time to clinically ready to be hospital discharged (CRBD) from study treatment initiation, disregarding prolonged hospitalization due solely to social factors.
Time frame: 45 days
Change From Baseline to 48 Hour Post Dose in Clinical Global Impression-Severity (CGI-S) of Hyponatremia Symptoms.
Change from baseline in blinded rater assessed CGI-S at 48 hours post-first dose or at discharge/rescue therapy, if earlier was assessed. The CGI-S is a one-question rating scale which was as follows: "Considering your total clinical experience with hyponatremia symptoms in this particular population, how symptomatic is the patient at this time?" 0=not assessed; 1=normal, not at all symtpmatic; 2=borderline symptomatic; 3=mildly symptomatic; 4=moderately symptomatic; 5=markedly symptomatic; 6=severely symptomatic; 7=among the most severly symptomatic patients.
Time frame: Baseline to 48 hours post dose
Change From Baseline to 24 and 72 Hours Post Dose in CGI-S of Hyponatremia Symptoms.
Change in CGI-S of hyponatremia symptoms from pretreatment baseline at 24 and 72 hours post-first dose, or at discharge/rescue therapy if earlier was assessed. The CGI-S is a one-question rating scale which was as follows: "Considering your total clinical experience with hyponatremia symptoms in this particular population, how symptomatic is the patient at this time?" 0=not assessed; 1=normal, not at all symtpmatic; 2=borderline symptomatic; 3=mildly symptomatic; 4=moderately symptomatic; 5=markedly symptomatic; 6=severely symptomatic; 7=among the most severly symptomatic patients.
Time frame: Baseline to 24 and 72 hours post dose
Change From Baseline to 48 Hours Post Dose in Clinical Global Impression - Improvement (CGI-I) Score of Hyponatremia Symptoms.
Change in CGI-I score at 48 hours post-first dose or discharge/rescue therapy, if earlier was assessed. The CGI-I is a one-question rating scale where the participant is asked to rate total improvement whether or not, in their judgment, it is due entirely to trial treatment. Compared to his/her condition at admission to the trial, how much has he/she changed? 0=not assessed; 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse
Time frame: Baseline to 48 hours post dose
Change From Baseline in Serum Sodium Concentration (24 Hour Area Under the Curve [AUC]).
Average 24 hour AUC of serum sodium concentration change from baseline, from Day 1 Hour 0 up to 72 hours post-first dose was assessed. A serum sodium sample was drawn at pre-treament and 8, 24, 48, and 72 hours post-first dose. Serum sodium was also assessed between 36 and 72 hours after the last dose. Analysis of AUC was for daily average AUC, hence the units or AUC are mEq/L/24 hours.
Time frame: 0 to 72 hours
Time to First 2-point Improvement in CGI-S Score.
CGI-S data up to 72 hours were used to identify 2-point improvements. Please refer to outcome measure 2 for details on the scale. For the analysis of time to first 2-point improvement in CGI-S, CGI-S data up to Hour 72 were used to identify 2-point improvements. Data for participants who received rescue therapy were censored at the time of receiving rescue therapy. For participants who were discharged before Hour 72 without reaching 2-point improvement in CGI-S, data were censored at the time of discharge. Other participants who did not reach the 2-point improvement during the 72 hours also had their data censored at their last CGI-S observations within 72 hours.
Time frame: Up to 72 hours
Percentage of Participants With Clinical Global Impression-Improvement (CGI-I) Score Improved to a Score of 1 or 2.
Percentage of responders (defined as CGI-I score of 1 = very much improved or 2 = much improved) at 48 hours post-first dose, or at discharge/rescue therapy, if earlier. Participants given rescue therapy were given a score of 7.
Time frame: 48 hours post dose
Percentage of Participants Requiring Rescue Therapy for Hyponatremia
Percentage of participants requiring rescue therapy within first 7 days of treatment for hyponatremia.
Time frame: 7 days
A total of 191 participants were recruited at 81 study sites in the United States (US). A total of 124 participants were randomised to treatment.
| Milestone | Tolvaptan 15-60 mg/Day | Placebo |
|---|---|---|
| Started | 66 | 58 |
| Completed | 53 | 48 |
| Not completed | 13 | 10 |
| Withdrew: Physician decision | 6 | 6 |
| Withdrew: Adverse event | 4 | 3 |
| Withdrew: Withdrawal by subject | 3 | 0 |
| Withdrew: Participant met withdrawal criteria | 0 | 1 |
LoS was time to clinically ready to be hospital discharged (CRBD) from study treatment initiation, disregarding prolonged hospitalization due solely to social factors.
| Days | Tolvaptan 15-60mg/Day | Placebo |
|---|---|---|
| Length of Hospital Stay (LoS) | 3.5 (3.0 to 4.5) | 4.0 (3.5 to 5.0) |
Change from baseline in blinded rater assessed CGI-S at 48 hours post-first dose or at discharge/rescue therapy, if earlier was assessed. The CGI-S is a one-question rating scale which was as follows: "Considering your total clinical experience with hyponatremia symptoms in this particular population, how symptomatic is the patient at this time?" 0=not assessed; 1=normal, not at all symtpmatic; 2=borderline symptomatic; 3=mildly symptomatic; 4=moderately symptomatic; 5=markedly symptomatic; 6=severely symptomatic; 7=among the most severly symptomatic patients.
| Units on a scale | Tolvaptan 15-60mg/Day | Placebo |
|---|---|---|
| Baseline | 4.0 (2.0 to 6.0) | 4.0 (3.0 to 6.0) |
| 48 hours post dose | 2.0 (1.0 to 6.0) | 3.0 (1.0 to 7.0) |
| Change from baseline | -1.0 (-3.0 to 3.0) | -1.0 (-3.0 to 3.0) |
Change in CGI-S of hyponatremia symptoms from pretreatment baseline at 24 and 72 hours post-first dose, or at discharge/rescue therapy if earlier was assessed. The CGI-S is a one-question rating scale which was as follows: "Considering your total clinical experience with hyponatremia symptoms in this particular population, how symptomatic is the patient at this time?" 0=not assessed; 1=normal, not at all symtpmatic; 2=borderline symptomatic; 3=mildly symptomatic; 4=moderately symptomatic; 5=markedly symptomatic; 6=severely symptomatic; 7=among the most severly symptomatic patients.
| Units on a scale | Tolvaptan 15-60mg/Day | Placebo |
|---|---|---|
| Baseline | 4.0 (2.0 to 6.0) | 4.0 (3.0 to 6.0) |
| 24 hours post-dose | 3.0 (1.0 to 6.0) | 3.0 (1.0 to 7.0) |
| Change from baseline at 24 hours | -1.0 (-3.0 to 3.0) | -1.0 (-3.0 to 2.0) |
| 72 hours post-dose | 2.0 (1.0 to 6.0) | 2.0 (1.0 to 7.0) |
| Change from baseline at 72 hours | -2.0 (-4.0 to 3.0) | -1.0 (-4.0 to 4.0) |
Change in CGI-I score at 48 hours post-first dose or discharge/rescue therapy, if earlier was assessed. The CGI-I is a one-question rating scale where the participant is asked to rate total improvement whether or not, in their judgment, it is due entirely to trial treatment. Compared to his/her condition at admission to the trial, how much has he/she changed? 0=not assessed; 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse
| Units on a scale | Tolvaptan 15-60mg/Day | Placebo |
|---|---|---|
| Change From Baseline to 48 Hours Post Dose in Clinical Global Impression - Improvement (CGI-I) Score of Hyponatremia Symptoms. | 2.0 (1.0 to 7.0) | 2.0 (1.0 to 7.0) |
Average 24 hour AUC of serum sodium concentration change from baseline, from Day 1 Hour 0 up to 72 hours post-first dose was assessed. A serum sodium sample was drawn at pre-treament and 8, 24, 48, and 72 hours post-first dose. Serum sodium was also assessed between 36 and 72 hours after the last dose. Analysis of AUC was for daily average AUC, hence the units or AUC are mEq/L/24 hours.
| mEq/L | Tolvaptan 15-60mg/Day | Placebo |
|---|---|---|
| Change From Baseline in Serum Sodium Concentration (24 Hour Area Under the Curve [AUC]). | 3.90 (-26.9 to 13.04) | 0.13 (-20.6 to 11.76) |
CGI-S data up to 72 hours were used to identify 2-point improvements. Please refer to outcome measure 2 for details on the scale. For the analysis of time to first 2-point improvement in CGI-S, CGI-S data up to Hour 72 were used to identify 2-point improvements. Data for participants who received rescue therapy were censored at the time of receiving rescue therapy. For participants who were discharged before Hour 72 without reaching 2-point improvement in CGI-S, data were censored at the time of discharge. Other participants who did not reach the 2-point improvement during the 72 hours also had their data censored at their last CGI-S observations within 72 hours.
| Hours | Tolvaptan 15-60mg/Day | Placebo |
|---|---|---|
| Time to First 2-point Improvement in CGI-S Score. | 51 (49 to 72) | 69 (49 to 73) |
Percentage of responders (defined as CGI-I score of 1 = very much improved or 2 = much improved) at 48 hours post-first dose, or at discharge/rescue therapy, if earlier. Participants given rescue therapy were given a score of 7.
| Percentage of participants | Tolvaptan 15-60mg/Day | Placebo |
|---|---|---|
| Percentage of Participants With Clinical Global Impression-Improvement (CGI-I) Score Improved to a Score of 1 or 2. | 57.8 | 52.7 |
Percentage of participants requiring rescue therapy within first 7 days of treatment for hyponatremia.
| Percentage of participants | Tolvaptan 15-60mg/Day | Placebo |
|---|---|---|
| Percentage of Participants Requiring Rescue Therapy for Hyponatremia | 3.03 | 9.09 |
Collected over Adverse events were recorded from the time the Informed Consent Form was signed up to 45 days after study drug administration.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tolvaptan 15-60 mg/Day | — | 18/66 (27.3%) | 52/66 (78.8%) |
| Placebo | — | 9/55 (16.4%) | 43/55 (78.2%) |
| Event | Tolvaptan 15-60 mg/Day | Placebo |
|---|---|---|
| Renal failure acuteRenal and urinary disorders | 3/66 | 1/55 |
| PneumoniaInfections and infestations | 2/66 | 0/55 |
| Septic shockInfections and infestations | 2/66 | 0/55 |
| HyponatraemiaMetabolism and nutrition disorders | 2/66 | 0/55 |
| Rapid correction of hyponatraemiaSurgical and medical procedures | 2/66 | 0/55 |
| Intestinal obstructionGastrointestinal disorders | 0/66 | 1/55 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 0/66 | 1/55 |
| Staphylococcal sepsisInfections and infestations | 0/66 | 1/55 |
| Femoral neck fractureInjury, poisoning and procedural complications | 0/66 | 1/55 |
| Lung cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/66 | 1/55 |
| Event | Tolvaptan 15-60 mg/Day | Placebo |
|---|---|---|
| ConstipationGastrointestinal disorders | 10/66 | 6/55 |
| HypotensionVascular disorders | 9/66 | 5/55 |
| DiarrhoeaGastrointestinal disorders | 3/66 | 5/55 |
| InsomniaPsychiatric disorders | 3/66 | 5/55 |
| NauseaGastrointestinal disorders | 5/66 | 3/55 |
| HypokalaemiaMetabolism and nutrition disorders | 5/66 | 4/55 |
| Oedema peripheralGeneral disorders | 4/66 | 4/55 |
| Abdominal distensionGastrointestinal disorders | 4/66 | 0/55 |
| Heart rate increasedInvestigations | 4/66 | 3/55 |
| HeadacheNervous system disorders | 4/66 | 3/55 |
| Age, Continuous(Years) | Tolvaptan 15-60 mg/Day | Placebo | Total |
|---|---|---|---|
| Mean | 65.7 ± 15.8 | 67.7 ± 15.6 | 66.7 ± 15.7 |
| Sex: Female, Male(Participants) | Tolvaptan 15-60 mg/Day | Placebo | Total |
|---|---|---|---|
| Female | 29 | 34 | 63 |
| Male | 37 | 24 | 61 |
The record gives a start of Oct 2010, a primary completion of May 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tolvaptan
Otsuka Pharmaceutical Development & Commercialization, Inc. →